Brain drug developer MapLight Therapeutics lost two-thirds of its market value Monday after unveiling clinical trial results that, while positive, raised doubts about whether one of its experimental ...

Argenx will acquire Forte Biosciences, the developer of an autoimmune disease drug that’s shown early promise, in a deal worth up to $2.2 billion. The Netherlands-based company said Monday it will ...

Today, a brief rundown of news involving Capricor Therapeutics and Legend Biotech, as well as updates from AstraZeneca, Outlook Therapeutics and Otsuka Pharmaceutical that you may have missed.

Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company ...